Antiretroviral Abacavir Linked With Cardiovascular Events in REPRIEVE Trial

(MedPage Today) -- People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of the REPRIEVE trial. Past use of abacavir increased...